India : Alembic Pharmaceuticals receives USFDA Approval for Bromfenac Ophthalmic Solution 0.09%.
Alembic Pharmaceuticals Limited announced that the Company has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Bromfenac Oph0thalmic Solution 0.09%. The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Bromday Ophthalmic Solution, 0.09%, of Bausch & Lomb Incorporated (Bausch & Lomb). Bromfenac Ophthalmic Solution 0.09% is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.
Bromfenac Ophthalmic Solution 0.09% has an estimated market size of US$ 6 million for twelve months ending December 2018 according to IQVIA.
Alembic now has a total of 96 ANDA approvals 84 final approvals and 12 tentative approvals) from USFDA.
[c] 2019 Al Bawaba (Albawaba.com) Provided by SyndiGate Media Inc. ( Syndigate.info ).
|Printer friendly Cite/link Email Feedback|
|Date:||Jun 29, 2019|
|Previous Article:||Israel,United States : Israel Railways Will Boost Passenger Safety and Operational Efficiency with New Work Group Communication Service from Motorola...|
|Next Article:||India : Alembic Pharmaceuticals receives USFDA Approval for Oseltamivir Phosphate Capsules USP. 30 mq (base), 45 mq (base), and 75 mq (base).|